| Expression pattern: |
DN |
| Associated gene: |
EIF4A3, SYNPO2 |
| Associated microRNA: |
- |
| Biological function: |
Tumor suppressor; inhibits GC cell proliferation, migration, invasion, cell cycle progression and xenograft tumor growth; promotes apoptosis. |
| Molecular mechanism: |
hsa_circ_0006847 exerts anticancer effects in the nucleus by binding/recruiting EIF4A3 and promoting the interaction of EIF4A3 with SYNPO2; the study indicates it is most likely not dependent on the ceRNA mechanism. |
| Biological pathway or process: |
proliferation (inhibits); migration (inhibits); invasion (inhibits); apoptosis (promotes); cell cycle (inhibits); metastasis (inhibits); other pathway/process (inhibits) |
| Detected method: |
Q
|
| Validation methods: |
Sanger Sequencing; RNase R Treatment; Actinomycin D / DRB Stability Assay; RT-qPCR; Nuclear-Cytoplasmic Fractionation; Clinical Sample Validation; RIP (RNA Immunoprecipitation); RNA Pull-Down; Co-IP; Transfection; CCK8; EdU Staining; Transwell Assay; Annexin V/PI Flow Cytometry; Cell Cycle Assay; Western Blot; In Vivo Animal Model; Survival Analysis; Bioinformatics Analysis |
| Clinical significance: |
hsa_circ_0006847 was associated with prognosis of GC patients; low expression was linked to poor overall survival and disease-free survival, and it may be a therapeutic target. |
| Description: |
hsa_circ_0006847/circASPHD1 is downregulated in gastric cancer tissues, plasma and cell lines and acts as a tumor suppressor. Its overexpression inhibits proliferation, migration, invasion, cell cycle progression and xenograft growth while promoting apoptosis, mainly through nuclear binding/recruitment of EIF4A3 and promotion of EIF4A3-SYNPO2 interaction. Low expression is associated with poorer prognosis, supporting its potential as a therapeutic target. |
| Confidence score: |
0.8689 |